Anderson Hoagland & Co. Sells 391 Shares of Zoetis Inc. (NYSE:ZTS)

Anderson Hoagland & Co. decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 1.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,242 shares of the company’s stock after selling 391 shares during the period. Anderson Hoagland & Co.’s holdings in Zoetis were worth $4,037,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Webster Bank N. A. boosted its stake in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after purchasing an additional 82 shares in the last quarter. Quarry LP increased its position in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares in the last quarter. Neo Ivy Capital Management purchased a new position in Zoetis during the fourth quarter valued at $40,000. LRI Investments LLC bought a new stake in Zoetis in the first quarter worth $43,000. Finally, Hazlett Burt & Watson Inc. increased its holdings in shares of Zoetis by 60.7% during the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after acquiring an additional 102 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

Shares of ZTS opened at $187.28 on Tuesday. The firm has a fifty day simple moving average of $187.30 and a two-hundred day simple moving average of $175.50. The firm has a market cap of $84.85 billion, a PE ratio of 36.08, a P/E/G ratio of 2.91 and a beta of 0.89. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter in the prior year, the business earned $1.41 earnings per share. Zoetis’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, equities analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on ZTS. Piper Sandler lifted their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. BTIG Research upped their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Stifel Nicolaus lifted their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Finally, Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $220.38.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.